Project IDs 46315, 50637, 46881
The overall goal of our Demonstration Project is to address the hypothesis that the gut microbiota plays a critical role in the pathogenesis of inflammatory bowel disease (IBD). To circumvent the confounding effects of mucosal inflammation and medications that independently bias microbial selection, we have set out to study a unique clinical model of ulcerative colitis (pouchitis) where the development and status of the gut microbiota can be assessed prospectively and relative to the outcome of disease. Pouchitis is an inflammatory condition of a surgicallycreated pseudorectum that is unique to ulcerative colitis and rarely occurs when this procedure is performed for treatment of other non-IBD diseases. Since the incidence of developing pouchitis within one year is over 50%, the likelihood of detecting antecedent changes in microbiota is high. Our multi-center study involves an integrated team of researchers with expertise in clinical manifestations of pouchitis (Univ. Chicago), cultivation of diverse microorganisms (MSU), molecular microbial ecology (MSU/UMich/MBL), and metagenomics (ANL). Our goal is to enroll up to 50 patients with pouchitis who will be followed clinically and endoscopically (sampling from the unprepped pouch) for a period of 18 months each. Though the use of highthroughput, cost-effective technologies, which members of this team have played a key role in developing, we intend to demonstrate a critical role for the gut microbiome in the development of the dysregulated mucosal immune response that is the hallmark of IBD. In order to identify associations between the structure and dynamics of the gut microbial community and specific clinical endpoints, we will scan for markers in the fecal microbial community that are associated with specific, quantifiable measures of disease activity or progression. Collectively, these studies will provide insights into how enteric microbiota cause or contribute to the etiopathogenesis of human ulcerative colitis. This knowledge will lead the way to novel ways to monitor patients with IBD and to guide the development of novel preventative and therapeutic interventions.
In accordance with the guidelines of the Human Microbiome Project (HMP), data generated by this study (NCBI Project ID 463154) will be subject to a 12 month publication moratorium from the date of data submission to dbGaP and SRA.
II.
DATA QUALITY:
The Marine Biological Laboratory used 454 Life sciences recursive phase algorithm "beta pipeline" to recover an average of 890,000 reads that extend from our proximal primers through "landmark" evolutionary conserved sequences GGATTAGATACCC (E. coli 785-797) for V3 -V5 amplicons (455 ± 50nt) or TGGGCGTAAAG (E. coli 565-575) for V6 -V4 amplicons (490nt ± 50nt). Our analyses quarantine and exclude reads that do not exactly match the MIDs (Multiplex Identifiers) or proximal rRNA primers, reads containing one or more ambiguous base calls (Ns), reads that exhibit greater than 2 mismatches to the evolutionary conserved sequences, and reads lacking the "landmark" evolutionary conserved sequences within 50 nt of their predicted position. Based upon benchmarking activities, these quality control procedures result in an average error rate of fewer than one error/ 500 positions. Remaining high quality reads are assigned taxonomy using GAST which quarantines sequences without valid BLAST hits within an alignment of over 80% of the read length. The sequence data from MBL will be submitted to dbGaP and to SRA and posted on VAMPS (http://vamps.mbl.edu).
For the shotgun metagenomic data analysis, Argonne National Laboratory's quality control is implemented through procedures used to include/exclude a particular sequenced read for subsequent analysis:
-Reads may not exhibit ambiguous base calls; those that do are removed from consideration.
-Reads that exhibit an uncharacteristic length -with respect to the particular sequencing platform used and/or to the distribution of lengths among all sequenced reads.
-Reads are screened to remove those that can be attributed to eukaryotic contamination; they are also screened to remove artificial duplicates.
III. DATA ANALYSIS AND PUBLICATION PLANS:
Data Analysis: For the shotgun metagenomic data analysis (Argonne), data are being processed through the MetagenomicsRASTServer (MG-RAST) to determine the functional and metabolic content of each biological sample. These functional and metabolic data are then examined with a variety of statistical tools (MG-RAST-stats) to identify correlations among the samples. Similarities and/or differences are then resolved to the responsible functional and/or metabolic pathway(s). The fidelity of such analyses is determined through the implementation of permutation (Monte-Carlo) based statistics. The goal of all analyses is to identify biologically meaningful differences among samples based on observed variation in their identified sequence content.
For analysis of functional genes, we are developing a functional gene dataset for each gene based on sequences extracted from HMP genomes and metagenomes, along with those from other major sequence repositories, and will automate regular updates of these datasets. We are using datasets to develop enhanced machine-learning classification tools similar to our naïve Bayesian 16S rRNA classifier (RDP Classifier) to provide more detailed taxonomic resolution of the functional gene data. Methods are being developed to determine shotgun metagenome coverage of the functional genes using gene-abundance curves fitted to the targeted functional gene metagenome data.
In order to identify associations between the structure and dynamics of the gut microbial community and specific clinical endpoints, we are employing approaches that have been broadly applied in genetic and gene expression studies for finding signatures of specific biological outcomes. In a manner analogous to gene expression or genome-wide association studies (GWAS) we are scanning for markers in the fecal microbial community that are associated with specific, quantifiable measures of disease activity or progression. For the purposes of our analysis, data generated by each of our analytic pathways will serve as analogous "markers" that will be associated with clinical variables/endpoints. Associations between individual markers (e.g. 16S V-region OTUs, metagenomic subsystems (MG-RAST), functional gene variants or specific cultivars) and quantitative clinical variables will be sought using data analysis models employed in statistical genetic analyses. The markers will initially be employed in a univariate analysis, but as analysis progresses, multivariate analysis will be performed.
Publication Plans: We hope to submit for publication the initial results of the metagenomic, 16S rRNA tag sequencing, cultivar, and functional gene analysis that describe the development of the pouch microbiome within the next 12 month before the termination of the embargo period.
IV. DATA RELEASE PLAN:
The data sharing plan will be coordinated by the Argonne National Laboratory, which will serve as the data coordination center for this consortium. The Argonne National Laboratory will be responsible for the sharing of data among consortium members and for upload of data to public databases such as dbGaP and SRA. We are working closely with the NIH and with the HMP Data Analysis and Coordination Center (DACC) to ensure that all required data is uploaded todbGaP and SRA. In our data management model, individual consortium members will be responsible for the data generated at each consortium site. The Argonne National Laboratory, in its role as data coordination center will be able to query each of the consortium databases for the purposes of analysis and also for transfer of data to the public HMP databases. We have budgeted for a limited amount of disk storage space required for initial analysis and data exchange, but have not budgeted the resources that would be required for long-term archival storage. We would anticipate that the HMP DACC will provide infrastructure and data standards for archival storage of data generated during this UH2/UH3 project.
The first release of clinical and sequence data from the UH2 phase to dbGaP and SRA occurred on May 25, 2010.
For each type of data, we anticipate the following data sharing/archive model:
• Clinical data: using the Velos system in place at the University of Chicago and University of Michigan, clinical data are being transferred to controlled access site dbGaP. The Velos system will provide security for information that remains at U of C and U of M. The upload and archiving of protected health information to databases other than those maintained by the U of C and U of M will only be done as required by the NIH/HMP. We anticipate that we will uploaded de-identified metadata to dbGaP to provide maximal utility for the uploaded sequence data.
• Sequence read and Picotitre TIFF files (the equivalent of sequence trace files for Sanger sequence) will be maintained at the sites that generated the data. Again, the Argonne National Laboratory will have the ability to access each of these individual databases and make the data available for consortium-wide analysis. These data will also be uploaded for archival storage at the HMP DACC if required and at Trace Archive. If, due to disk space requirements, any of this data were to be destroyed, this would not be done without consultation with the NIH project managers to ensure that archiving via the HMP DACC is completed. Metadata associated with any of sequence data (primarily the clinical data from the U of C that is maintained on Velos) will be linked via the Argonne National Laboratory data coordination efforts. These metadata and the links to the sequence data will also be transferred to dbGaP.
• Cultivars from high throughput culture as performed at MSU will be stored at the MSU by the investigators located there. These cultivars will be made available to the awardees of the U54 genome sequencing centers awarded under RFA-RM-08-001, and any other HMP-funded researchers. Once results are published in a peer-reviewed journal, any isolates that described will be made available to the general research community. In addition, these isolates will be deposited in BEI/ATCC, which has been contracted to be the repository for HMP reference isolates.
• The results of analysis will be prepared for publication in peer-reviewed journals by the consortium. Much of the data analysis will be available in web-based format. The results of 16S tag sequencing analysis will be on the VAMPS site maintained by the MBL. The metagenomics analysis will be on the MG-RAST server maintained by ANL. Functional gene data analysis will be available on the site maintained by MSU. In accordance with the stated goals of the Human Microbiome Project, the data generated will be released to the public in a timely manner. Similarly, intellectual property issues will be dealt with by each institution in a manner that maximized public benefit of the data produced and the tools that are developed to deal with type of data. The consortium members have an outstanding track record of making data and analysis tools available to the public as exemplified the Ribosomal Database Project, SEED and the metagenomics RAST server and the VAMPS website.
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